Tumor targeting of functionalized lipid nanoparticles: Assessment by in vivo fluorescence imaging

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 75, Issue 2, 2010, Pages 137-147

  Goutayer, Mathieu ^a   Dufort, Sandrine ^b,c   Josserand, Véronique ^b   Royère, Audrey ^d   Heinrich, Emilie ^a   Vinet, Françoise ^a   Bibette, Jérôme ^d   Coll, Jean Luc ^b   Texier, Isabelle ^a  

^a CEA GRENOBLE   (France)

^b INSTITUT ALBERT BONNIOT   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d PSL RESEARCH UNIVERSITY   (France)

Author keywords

Cellular targeting; CRGD functionalization; Fluorescence imaging; In vivo targeting; Lipid nanoparticles; Tumor nanoparticle uptake

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; LIPID NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RETENTION; DRUG SPECIFICITY; DRUG TARGETING; FEMALE; FLUORESCENCE ANALYSIS; FLUORESCENCE IMAGING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOPHARMACEUTICS; NONHUMAN; TUMOR XENOGRAFT;

ANIMALS; DRUG DELIVERY SYSTEMS; FEMALE; FLUORESCENT DYES; HUMANS; INJECTIONS, INTRAVENOUS; INTEGRIN ALPHAVBETA3; LIPIDS; MALEIMIDES; MICE; MICE, NUDE; NANOPARTICLES; PEPTIDES, CYCLIC; SURFACE-ACTIVE AGENTS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952952258     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.02.007     Document Type: Article

References (55)

1. Torchilin V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 2006, 58:1532-1555.
2. Couvreur P., Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 2006, 23:1417-1450.
3. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
4. Jiang W., Kim B.Y., Rutka J.T., Chan W.C. Advances and challenges of nanotechnology-based drug delivery system. Expert Opin. Drug Deliv. 2007, 4:621-633.
5. Müller R.H., Radtke M., Wissing S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 2002, 242:121-128.
6. Müller R.H., Radtke M., Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002, 54:S131-S155.
7. Düzgünes N. Lipid assemblies for drug delivery. Adv. Drug Deliv. Rev. 2001, 137-138.
8. Torchilin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 2007, 24:1-15.
9. Glickson J.D., Lund-Katz S., Zhou R., Choi H.S., Chen I.W., Li H., Corbin I., Popov A.V., Cao W., Song L., Qi C., Marotta D., Nelson D.S., Chen J., Chance B., Zheng G. Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents. Mol. Imag. 2008, 7:101-110.
10. Frias J.C., Lipinski M.J., Lipinski S.E., Albeda M.T. Modified lipoproteins as contrast agents for imaging atherosclerosis. Contrast Media Mol. Imag. 2007, 2:16-23.
11. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
12. Heuschkel S., Goebel A., Neubert R.H. Microemulsions-modern colloidal carrier for dermal and transdermal drug delivery. J. Pharm. Sci. 2008, 97:603-631.
13. Mason T.G., Wilking J.N., Meleson K., Chang C.B., Graves S.M. Nanoemulsions: formation, structure, and physical properties. J. Phys. Condens. Mater. 2006, 18:R635-R666.
14. Tamilvanan S. Oil-in-water lipid emulsions: implications for parenteral and ocular delivering systems (review). Prog. Lipid Res. 2004, 43:489-533.
15. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
16. Wong H.L., Bendayan R., Rauth A., Li Y., Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 2007, 59:491-504.
17. Heurtault B., Saulnier P., Pech B., Proust J.-E., Benoit J.-P. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm. Res. 2002, 19:875-880.
18. Liu S., Wang S., Lu R. Lipoproteins as pharmaceutical carriers. Nanoparticles as Drug Carriers 2006, Imperial Press College. V.P. Torchilin (Ed.).
19. Heurtault B., Saulnier P., Pech B., Proust J.-E., Benoit J.-P. Physico-chemical stability of colloidal lipid particles. Biomaterials 2003, 24:4283-4300.
20. Texier I., Goutayer M., Da Silva A., Guyon L., Djaker N., Josserand V., Neumann E., Bibette J., Vinet F. Cyanine loaded lipid nanoparticles for improved in vivo fluorescence imaging. J. Biomed. Opt. 2009, 14:054005.
21. Massoud T.F., Gambhir S.S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003, 17:545-580.
22. Rao J., Dragulescu-Andrasi A., Yao H. Fluorescence imaging in vivo: recent advances. Curr. Opin. Biotechnol. 2007, 18:17-25.
23. Rudin M., Rausch M., Stoeckli M. Molecular imaging in drug discovery and development: potential and limitations of nonnuclear methods. Mol. Imag. Biol. 2005, 7:5-13.
24. 3-integrin expression in vivo. Acc. Chem. Res. 2009, 42:969-980.
25. 3 expression. Cancer Metast. Rev. 2008, 27:631-644.
26. Temming K., Schiffelers R.M., Molema G., Kok R. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumor vasculature. Drug Resist. Updates 2005, 8:381-402.
27. Haubner R., Gratias R., Diefenbach B., Goodman S., Jonczyk A., Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin avb3 antagonists. J. Am. Chem. Soc. 1996, 118:7461-7472.
28. 3 integrin for a new cancer therapy. Angew. Chem. Int. Ed. 1997, 36:1374-1389.
29. Jin Z.H., Josserand V., Foillard S., Boturyn D., Dumy P., Favrot M.C., Coll J.L. In vivo optical imaging of integrin alpha(v)-beta(3) in mice using multivalent or monovalent cRGD targeting vectors. Mol. Cancer 2007, 6. 10.1186/1476-4598-6-41.
30. Jin Z.-H., Razkin J., Josserand V., Boturyn D., Grichine A., Texier I., Favrot M., Dumy P., Coll J.L. In vivo noninvasive optical imaging of receptor-mediated RGD internalization using self-quenched Cy5-labeled RAFT-c-(-RGDfK-)4. Mol. Imag. 2007, 6:43-55.
31. Razkin J., Josserand V., Boturyn D., Jin Z., Dumy P., Favrot M., Coll J.L., Texier I. Activatable fluorescent probes for tumor-targeting imaging in live mice. ChemMedChem 2006, 1:1069-1072.
32. Sancey L., Ardisson V., Riou L.M., Ahmadi M., Marti-Batlle D., Boturyn D., Dumy P., Fagret D., Ghezzi C., Vuillez J.P. In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta(3) integrin-targeted tracer Tc-99m-RAFT-RGD. Eur. J. Nucl. Med. Mol. Imag. 2007, 34:2037-2047.
33. Sens R., Drexhage K.H. Fluorescence quantum yield of oxazine and carbazine laser dyes. J. Lumin. 1981, 24-25:709-712.
34. Jin Z.H., Josserand V., Razkin J., Garanger E., Boturyn D., Favrot M.C., Dumy P., Coll J.L. Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)(4). Mol. Imag. 2006, 5:188-197.
35. Texier I., Josserand V., Garanger E., Razkin J., Jin Z., Dumy P., Favrot M., Boturyn D., Coll J.-L. Luminescent probes for optical in vivo imaging. Proc. SPIE 2005, 5704:16-23.
36. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
37. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
38. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
39. Decuzzi P., Pasqualini R., Arap W., Ferrari M. Intravascular delivery of nanoparticulate systems: does geometry really matter?. Pharm. Res. 2008, 10.1007/s11095-008-9697-x.
40. Faure A.-C., Dufort S., Josserand V., Perriat P., Coll J.L., Roux S., Tillement O. Control of the in vivo biodistribution of hybrid nanoparticles with different poly(ethyleneglycol) coatings. Small 2009, 5:2565-2575.
41. Hamidi M., Azadi A., Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv. 2006, 13:399-409.
42. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
43. Monfardini C., Veronese F.M. Stabilization of substances in circulation. Bioconjug. Chem. 1998, 9:418-450.
44. Anton N., Benoit J.P., Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates - a review. J. Control. Release 2008, 128:185-194.
45. Sajjadi S. Nanoemulsion formation by phase inversion emulsification: on the nature of inversion. Langmuir 2006, 22:5597-5603.
46. Wang L., Li X., Zhang G., Dong J., Eastoe J. Oil-in-water nanoemulsions for pesticide formulations. J. Colloid Interf. Sci. 2007, 314:230-235.
47. Jafari S.M., He Y.H., Bhandari B. Nano-emulsion production by sonication and microfluidization - a comparison. Int. J. Food Prop. 2006, 9:475-485.
48. Weissleder R., Wang Y.M., Papisov M., Bogdanov A., Schaffer B., Brady T.J., Wittenberg J. Polymeric contrast agents for MR imaging of adrenal glands. JMRI - J. Magn. Reson. Imag. 1993, 3:93-97.
49. Daou T.J., Li L., Reiss P., Josserand V., Texier I. Effect of poly(ethylene glycol) length on the in vivo behavior of coated quantum dots. Langmuir 2009, 25:3040-3044.
50. McNeeley K.M., Annapragada A., Bellamkonda R.V. Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. Nanotechnology 2007, 18:385101.
51. Sawant R.R., Sawant R.M., Kale A.A., Torchilin V.P. The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells. J. Drug Target. 2008, 16:596-600.
52. Boturyn D., Coll J.L., Garanger E., Favrot M., Dumy P. Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J. Am. Chem. Soc. 2004, 126:5730-5739.
53. 3 integrin ligands. Org. Biomol. Chem. 2006, 4:1958-1965.
54. Garanger E., Boturyn D., Jin Z., Dumy P., Favrot M., Coll J.L. New multifunctional molecular conjugate vector for targeting, imaging and therapy of tumors. Mol. Ther. 2005, 12:1168-1175.
55. 3 expression in living mice. Bioconjug. Chem. 2005, 16:1433-1441.